BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
News|Articles|June 2, 2004
- Pharmaceutical Technology-06-02-2004
- Volume 28
- Issue 6
Will CROs Take On the Risks of Strategic Outsourcing?
Author(s)Jim Miller
It's not clear whether contract service providers can deliver the performance improvements and costs savings that drug companies expect from large, long-term, semi-exclusive contracts.
Advertisement
Articles in this issue
over 22 years ago
Microbial Testing in Support of Aseptic Processingover 22 years ago
June 2004over 22 years ago
Uniformity of Bioprocessing Equipment Manufacturingover 22 years ago
Research Tips To Find Packaging Facts Fastover 22 years ago
New Technologies Optimize Biotech Process Efficiencyover 22 years ago
Battles Escalate Over Prescription Drug Importsover 22 years ago
USP's Semi-Hemiquinquennial Meetingover 22 years ago
In the Spotlight - June 2004Advertisement
Related to this article
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, raising oversight questions for pharma teams.
Advertisement
Advertisement